EW•benzinga•
Heart Devices-Focused Edwards Lifesciences Confident in 2025 Outlook, Analyst Sees Long-Term Strength
Summary
Edwards Lifesciences beat Q4 estimates with $1.39B in sales, driven by growth in TMTT, TAVR, and Surgical. The company projects continued expansion in 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 12, 2025 by benzinga